Summary:
- Carolina Wealth Advisors, LLC bought $6.01 million worth of Novo Nordisk A/S shares on October 07, 2025.
- The purchase increased their stake in Novo Nordisk to 2.8% of the fund’s AUM as of Q3 2025.
- Novo Nordisk is a global healthcare leader specializing in diabetes and obesity care with a diversified product portfolio.
Rewritten Article:
Carolina Wealth Advisors, LLC made a significant investment move on October 07, 2025, by acquiring shares worth $6.01 million in Novo Nordisk A/S (NYSE: NVO). This purchase, as disclosed in a U.S. Securities and Exchange Commission (SEC) filing, added 102,629 shares to their portfolio during the third quarter. The estimated trade size was calculated based on the average closing price from July 1 through September 30, 2025, bringing their total holding to 116,973 shares.
With this transaction, Novo Nordisk now represents 2.8% of Carolina Wealth Advisors’ 13F reportable assets under management as of Q3 2025. This buy places Novo Nordisk as the 11th-largest holding in the firm’s overall portfolio and the sixth-largest stock holding. Notably, Novo Nordisk’s stock price stood at $59.65 as of October 6, 2025, reflecting a 65.4% underperformance compared to the S&P 500 over the past year.
Novo Nordisk is a renowned global healthcare company specializing in diabetes and obesity care, offering a range of pharmaceutical products and medical devices for chronic disease management. With a strong focus on research and development, Novo Nordisk serves healthcare providers, hospitals, and patients worldwide, catering to individuals with diabetes, obesity, and rare diseases. The company’s scale, diversified product portfolio, and global presence position it as a leader in the healthcare industry.
Carolina Wealth Advisors’ strategic investment in Novo Nordisk underscores their confidence in the company’s growth potential amidst market fluctuations. As Novo Nordisk continues to innovate and expand its pipeline of treatments, investors like Carolina Wealth Advisors see an opportunity for long-term value. With Novo Nordisk trading at a more reasonable valuation compared to previous highs, this acquisition could prove to be strategic in the firm’s investment portfolio.
